Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Milind Javle, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1998- University at BuffaloResidency, Internal Medicine, 1993 - 1994
Grant Medical CollegeClass of 1991
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2025 - 2027
GA State Medical License 2025 - 2027
MS State Medical License 2025 - 2027
OK State Medical License 2020 - 2027
AL State Medical License 2025 - 2026
LA State Medical License 2025 - 2026
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2014
Publications & Presentations
PubMed
- 5 citationsImproved Outcomes Following Resection of Perihilar Cholangiocarcinoma: A 27-Year Experience.Anish J Jain, Mateo Lendoire, Antony Haddad, Ching-Wei D Tzeng, Artem Boyev
Annals of Surgical Oncology. 2025-06-01 - 3 citationsTransplantation for Peri-Hilar and Intrahepatic Cholangiocarcinoma With mTOR Immunosuppression.Samar Semaan, Ashton A Connor, Ashish Saharia, Sudha Kodali, Ahmed Elaileh
Transplantation Proceedings. 2025-03-01 - 3 citationsNeoadjuvant Multiagent Systemic Therapy Approach to Liver Transplantation for Perihilar Cholangiocarcinoma.Nadine Soliman, Ashton A Connor, Ashish Saharia, Sudha Kodali, Ahmed Elaileh
Transplantation Direct. 2025-03-01
Authored Content
- Response and Survival Associated with First-Line FOLFIRINOX vs GemcitabineJuly 2020
- Response and Survival Associated with First-Line FOLFIRINOX vs GemcitabineJuly 2020
Press Mentions
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) Against Cholangiocarcinoma on LancetDecember 5th, 2025- Gallbladder Cancer: 9 Facts About Symptoms, Diagnosis and TreatmentDecember 6th, 2023
- MD Anderson Research Highlights for August 11, 2021August 11th, 2021
